APL-2, a complement C3 inhibitor, may potentially reduce both intravascular and extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria

Publication date: September 2017
Source:Molecular Immunology, Volume 89
Author(s): Delphine El Mehdi, Federico V. Grossi, Pascal Deschatelets, Humphrey Pullon, Lisa Tan, Carolina A. Vega, Cedric G. Francois




http://ift.tt/2euZZWc